Lilliam Ambroggio1, Matthew Test2, Joshua P Metlay3, Thomas R Graf4, Mary Ann Blosky4, Maurizio Macaluso5, Samir S Shah6. 1. Division of Hospital Medicine Division of Biostatistics and Epidemiology Department of Pediatrics, the University of Cincinnati College of Medicine, Ohio. 2. Division of Hospital Medicine. 3. General Medicine Division, Massachusetts General Hospital, Boston. 4. Population Health, Geisinger Health System, Danville, Pennsylvania. 5. Division of Biostatistics and Epidemiology Department of Pediatrics, the University of Cincinnati College of Medicine, Ohio. 6. Division of Hospital Medicine Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center Department of Pediatrics, the University of Cincinnati College of Medicine, Ohio.
Abstract
BACKGROUND: The role of adjunct systemic corticosteroid therapy in children with community-acquired pneumonia (CAP) is not known. The objective was to determine the association between adjunct systemic corticosteroid therapy and treatment failure in children who received antibiotics for treatment of CAP in the outpatient setting. METHODS: The study included a retrospective cohort study of children, aged 1-18 years, with a diagnosis of CAP who were managed at an outpatient practice affiliated with Geisinger Health System from January 1, 2008 to January 31, 2010. The primary exposure was the receipt of adjunct corticosteroid therapy. The primary outcome was treatment failure defined as a respiratory-associated follow-up within 14 days of diagnosis in which the participant received a change in antibiotic therapy. The probability of receiving adjunct systemic corticosteroid therapy was calculated using a matched propensity score. A multivariable conditional logistic regression model was used to estimate the association between adjunct corticosteroids and treatment failure. RESULTS: Of 2244 children with CAP, 293 (13%) received adjunct corticosteroids, 517 (23%) had underlying asthma, and 624 (28%) presented with wheezing. Most patients received macrolide monotherapy for their CAP diagnosis (n = 1329; 59%). Overall, treatment failure was not associated with adjunct corticosteroid treatment (odds ratio [OR], 1.72; 95% confidence interval [CI], 0.93 and 3.19), but the association was statistically significant among patients with no history of asthma (OR, 2.38; 95% CI, 1.03 and 5.52), with no statistical association among patients with a history of asthma. CONCLUSION: Adjunct corticosteroid therapy was associated with treatment failure among children diagnosed with CAP who did not have underlying asthma.
BACKGROUND: The role of adjunct systemic corticosteroid therapy in children with community-acquired pneumonia (CAP) is not known. The objective was to determine the association between adjunct systemic corticosteroid therapy and treatment failure in children who received antibiotics for treatment of CAP in the outpatient setting. METHODS: The study included a retrospective cohort study of children, aged 1-18 years, with a diagnosis of CAP who were managed at an outpatient practice affiliated with Geisinger Health System from January 1, 2008 to January 31, 2010. The primary exposure was the receipt of adjunct corticosteroid therapy. The primary outcome was treatment failure defined as a respiratory-associated follow-up within 14 days of diagnosis in which the participant received a change in antibiotic therapy. The probability of receiving adjunct systemic corticosteroid therapy was calculated using a matched propensity score. A multivariable conditional logistic regression model was used to estimate the association between adjunct corticosteroids and treatment failure. RESULTS: Of 2244 children with CAP, 293 (13%) received adjunct corticosteroids, 517 (23%) had underlying asthma, and 624 (28%) presented with wheezing. Most patients received macrolide monotherapy for their CAP diagnosis (n = 1329; 59%). Overall, treatment failure was not associated with adjunct corticosteroid treatment (odds ratio [OR], 1.72; 95% confidence interval [CI], 0.93 and 3.19), but the association was statistically significant among patients with no history of asthma (OR, 2.38; 95% CI, 1.03 and 5.52), with no statistical association among patients with a history of asthma. CONCLUSION: Adjunct corticosteroid therapy was associated with treatment failure among children diagnosed with CAP who did not have underlying asthma.
Authors: Sherry Weitzen; Kate L Lapane; Alicia Y Toledano; Anne L Hume; Vincent Mor Journal: Pharmacoepidemiol Drug Saf Date: 2004-12 Impact factor: 2.890
Authors: Tobias Kurth; Alexander M Walker; Robert J Glynn; K Arnold Chan; J Michael Gaziano; Klaus Berger; James M Robins Journal: Am J Epidemiol Date: 2005-12-21 Impact factor: 4.897
Authors: Jayachandran Panickar; Monica Lakhanpaul; Paul C Lambert; Priti Kenia; Terence Stephenson; Alan Smyth; Jonathan Grigg Journal: N Engl J Med Date: 2009-01-22 Impact factor: 91.245
Authors: Anna K Weiss; Matthew Hall; Grace E Lee; Matthew P Kronman; Seth Sheffler-Collins; Samir S Shah Journal: Pediatrics Date: 2011-01-10 Impact factor: 7.124
Authors: Malte Kohns Vasconcelos; Patrick M Meyer Sauteur; Regina Santoro; Michael Coslovsky; Marco Lurà; Kristina Keitel; Tanja Wachinger; Svetlana Beglinger; Ulrich Heininger; Johannes van den Anker; Julia Anna Bielicki Journal: BMJ Open Date: 2020-12-29 Impact factor: 2.692